Stoke therapeutics stock.
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of …
Find the latest Autolus Therapeutics plc (AUTL) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics Inc’s ( STOK) price is currently down 10.24% so far this month. During the month of March, Stoke Therapeutics Inc’s stock price has reached a high of $9.99 and a low of $7.22. Over the last year, Stoke Therapeutics Inc has hit prices as high as $24.97 and as low as $6.88. Year to date, Stoke Therapeutics Inc’s stock is ...Investing in the stock market takes a lot of courage, a lot of research, and a lot of wisdom. One of the most important steps is understanding how a stock has performed in the past. Of course, the past is not a guarantee of future performan...Stoke Therapeutics (STOK) (Delayed Data from NSDQ) $3.79 USD -0.06 (-1.56%) Updated Nov 30, 2023 04:00 PM ET After-Market: $3.77 -0.02 (-0.53%) 5:10 PM …
Nov 8, 2023 · Stoke Therapeutics (STOK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Thomas Shrader from BTIG remains neutral on the stock and ... Find the latest Coya Therapeutics, Inc. (COYA) stock quote, history, news and other vital information to help you with your stock trading and investing.
View the latest Stoke Therapeutics Inc. (STOK) stock price, news, historical charts, analyst ratings and financial information from WSJ.
Stoke Therapeutics Stock Forecast. ... According to 7 stock analysts, the average 12-month stock price forecast for STOK stock stock is $21, which predicts an ...Find the latest Coya Therapeutics, Inc. (COYA) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.67. See the top stocks recommended by analysts >> The company has a one-year high of $26.60 and a ...Find the latest AN2 Therapeutics, Inc. (ANTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Track Sorrento Therapeutics Inc (SRNEQ) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors
Jul. 25, 2023, 12:51 PM. Stoke Therapeutics Inc (NASDAQ:STOK) shares are trading lower after the company released new safety & efficacy data from STK-001 in the Phase 1/2a Studies (MONARCH ...
Nov 29, 2022 · BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 29, 2022-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that seven abstracts related to the Company’s work in Dravet syndrome have been accepted ... Find the latest Context Therapeutics Inc. (CNTX) stock quote, history, news and other vital information to help you with your stock trading and investing.Stoke Therapeutics (NASDAQ:STOK) Second Quarter 2023 ResultsKey Financial Results. Net loss: US$30.7m (loss widened by 24% from 2Q 2022). US$0.69 loss per share (further deteriorated from US$0.63 ...BEDFORD, Mass.--(BUSINESS WIRE)--Nov. 21, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that presentations related to the Company’s work in Dravet syndrome will be presented at ...BEDFORD - Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by …19 Nov 2020 ... Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by ...Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 8.1% so far this month. During the month of March, Stoke Therapeutics Inc’s stock price has reached a high of $9.99 and a low of $8.09. Over the last year, Stoke Therapeutics Inc has hit prices as high as $26.60 and as low as $6.88. …
Stoke Media & Investor Contacts: Dawn Kalmar Chief Communications Officer [email protected] 781-303-8302 Eric Rojas Vice President, Investor Relations [email protected] 617-312-2754 Source: Stoke Therapeutics, Inc.Find the latest Stoke Therapeutics, Inc. (STOK) stock quote, history, news and other vital information to help you with your stock trading and investing.Option Exchange Program Overview • Equity is an important component of your Total Rewards package at Stoke • Many stock options granted to date are “underwater” • That means the exercise price is lower than the current stock price • You are our most important asset - Significantly underwater stock options may not effectively ...Stock analysis for Stoke Therapeutics Inc (STOK:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.Stoke Therapeutics Stock Falls Post Early Efficacy Data From Lead Dravet Syndrome Program. ... Stoke had approximately $252.2 million in cash, cash equivalents, marketable securities, and ...
Find the latest Context Therapeutics Inc. (CNTX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Jul 24, 2023 · Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ... Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...If you’re just getting started, tracking investments might seem like a mystery. Thankfully, modern tools and technology make it easier than ever to figure out how to manage your stock portfolio and to track it. This quick guide gives you ti...Stoke Therapeutics (Nasdaq: STOK), is a biotechnology company dedicated to addressing the underlying cause of severe diseases. The company is pursuing an entirely new approach to treating severe ... Ed Kaye, Stoke Therapeutics CEO. November 14, 2022 07:00 AM EST Updated 09:38 AM. R&D. Stoke teases early efficacy data for possible PhIII dose in lead Dravet syndrome program.Find the latest Aldeyra Therapeutics, Inc. (ALDX) stock quote, history, news and other vital information to help you with your stock trading and investing.Analysts who have issued ratings on the stock over the past year have set an average 1-year target price of $23.50. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000.
Sep 14, 2023 · Analysts who have issued ratings on the stock over the past year have set an average 1-year target price of $23.50. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000.
STOK Earnings Date and Information. Stoke Therapeutics last posted its quarterly earnings data on November 7th, 2023. The reported ($0.55) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.65) by $0.10. The business earned $3.31 million during the quarter, compared to analyst estimates of $3.83 million.
Jul 24, 2023 · Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ... Find the latest vTv Therapeutics Inc. (VTVT) stock quote, history, news and other vital information to help you with your stock trading and investing.Cookie Duration Description; _ga: 2 years: The _ga cookie, installed by Google Analytics, calculates visitor, session and campaign data and also keeps track of site usage for the site's analytics report.MDNA11 is the company’s albumin-fused, long-acting, IL-2 agonist that. Find the latest Medicenna Therapeutics Corp. (MDNA) stock quote, history, news and other vital information to help you with ...Sep 14, 2023 · Analysts who have issued ratings on the stock over the past year have set an average 1-year target price of $23.50. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000. Stoke Therapeutics Inc Stock Price History. Stoke Therapeutics Inc’s price is currently down 10.35% so far this month. During the month of July, Stoke Therapeutics Inc’s stock price has reached a high of $12.45 and a low of $9.49. Over the last year, Stoke Therapeutics Inc has hit prices as high as $22.87 and as low as $6.88. Year to date ...34.02%. Get the latest Stoke Therapeutics Inc (STOK) real-time quote, historical performance, charts, and other financial information to help you make more informed …Seth currently serves on the boards of Akero Therapeutics and Stoke Therapeutics as well as the boards of the 15 portfolio companies created within ATP’s current fund to date. From 2002 to 2010, he was a member of the board of the International Partnership for Microbicides, a nonprofit product development partnership focused on women’s ...Granahan Investment Management LLC lowered its holdings in Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) by 11.7% during the 2nd quarter, according to the company in its most recent ...
The Stoke Therapeutics, Inc. stock price fell by -6.47% on the last day (Tuesday, 21st Nov 2023) from $4.17 to $3.90. During the last trading day the stock fluctuated 5.91% from a day low at $3.89 to a day high of $4.12. The price has fallen in 7 of the last 10 days and is down by -19.59% for this period. Volume has increased on the last day by ...Arthur Levin STOK stock SEC Form 4 insiders trading. Arthur has made over 11 trades of the Stoke Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 100 units of STOK stock worth $124 on 15 March 2023.. The largest trade he's ever made was exercising 80,000 units of Stoke …Dec 1, 2023 · Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced highlights from presentations of clinical data at the American Epilepsy Society (AES) 2023 Annual Meeting December 1 – 5, in Orlando, Florida. In other news, insider Barry Ticho sold 15,000 shares of Stoke Therapeutics’ stock on July 3rd at an average price of $10.60 per share. The total value of this transaction amounted to $159,000. Following this sale, Ticho now owns 25,895 shares in the company with a valuation of $274,487. This transaction was disclosed through a …Instagram:https://instagram. stoksssmith and wesson holding corp stocktemporary motorcycle insurancebest wind and hail insurance Arthur Levin STOK stock SEC Form 4 insiders trading. Arthur has made over 11 trades of the Stoke Therapeutics stock since 2021, according to the Form 4 filled with the SEC. Most recently he exercised 100 units of STOK stock worth $124 on 15 March 2023.. The largest trade he's ever made was exercising 80,000 units of Stoke …BEDFORD, Mass.--(BUSINESS WIRE)--Mar. 6, 2023-- Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today reported financial results for the full year ended December 31, 2022 and provided business updates. carnival.stockcasey stock BEDFORD, Mass., December 01, 2023--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein ...11 Nov 2023 ... Since July 2023, shares of Stoke's common stock have declined in value from a trading price of over $10.00 per share to a current trading price ... robinhood shiba inu Find the latest 4D Molecular Therapeutics, Inc. (FDMT) stock quote, history, news and other vital information to help you with your stock trading and investing.Find the latest vTv Therapeutics Inc. (VTVT) stock quote, history, news and other vital information to help you with your stock trading and investing.